Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.33 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | PGD | P52209 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HMGCR | P04035 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15220069 | 0.81 | SLC22A6 (0.38) | TSHRCYP2D6CYP2C19HIF1ASLC22A6 | |
| SCHEMBL10616009 | 0.79 | TSHR (0.33) | TSHRCYP2D6CYP2C19HIF1AALDH1A1 | |
| SCHEMBL249850 | 0.76 | TSHR (0.39) | TSHRCYP2D6CYP2C19HIF1ASLC22A6 | |
| SCHEMBL8372729 | 0.76 | TSHR (0.39) | TSHRCYP2D6CYP2C19HIF1ASLC22A6 | |
| SCHEMBL23913764 | 0.75 | SLC22A6 (0.41) | TSHRCYP2D6CYP2C19HIF1ASLC22A6 | |
| SCHEMBL20711453 | 0.75 | SLC22A6 (0.41) | TSHRCYP2D6CYP2C19HIF1ASLC22A6 | |
| SCHEMBL1572820 | 0.75 | SLC22A6 (0.41) | TSHRCYP2D6CYP2C19HIF1ASLC22A6 | |
| SCHEMBL1300987 | 0.74 | TSHR (0.39) | TSHRCYP2D6CYP2C19HIF1ASLC22A6 | |
| Ammonia Solution, Strong SCHEMBL8858462 | 0.74 | TDP1 (0.40) | TSHRCYP2D6CYP2C19HIF1ASLC22A6 | |
| Ammonia Solution, Strong SCHEMBL8858461 | 0.74 | TDP1 (0.40) | TSHRCYP2D6CYP2C19HIF1ASLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1885817-B1 | RESPONSIVE LUMINESCENT LANTHANIDE COMPLEXES | UNIV DURHAM (GB) | 2016-05-11 | — | — | EP | disclosed |
| US-8193174-B2 | Responsive luminescent lanthanide complexes | UNIVERSITY OF DURHAM (GB) | 2012-06-05 | — | — | US | disclosed |
| US-7666898-B2 | Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors | ILYPSA, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090318492-A1 | INDOLE COMPOUNDS HAVING C4-ACIDIC SUBSTITUENTS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | ILYPSA, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20080312431-A1 | Responsive Luminescent Lanthanide Complexes | UNIVERSITY OF DURHAM (GB) | 2008-12-18 | — | — | US | disclosed |
| EP-1960356-A2 | MULTIVALENT INDOLE COMPOUNDS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | Ilypsa, Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1951315-A2 | PHOSPHOLIPASE INHIBITORS, INCLUDING MULTI-VALENT PHOSPHOLIPASE INHIBITORS, AND USE THEREOF, INCLUDING AS LUMEN-LOCALIZED PHOSPHOLIPASE INHIBITORS | Ilypsa, Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1948604-A1 | INDOLE COMPOUNDS HAVING C4-ACIDIC SUBSTITUENTS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | Ilypsa, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1885817-A1 | RESPONSIVE LUMINESCENT LANTHANIDE COMPLEXES | UNIVERSITY OF DURHAM (GB) | 2008-02-13 | — | — | EP | disclosed |
| US-20070135385-A1 | Methyl indoxam; obesity; dietectics; antidiabetic agents; insulin resistance; non-insulin dependent diabetes; glucose intolerance; hypercholesterolemia; hypertriglyceridemia; anticholesterol agents; metabolic disorders; foods;bioavailability; side effect reduction | ILYPSA, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070135383-A1 | Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors | ILYPSA, INC. | 2007-06-14 | — | — | US | disclosed |
| WO-2007056279-A2 | PHOSPHOLIPASE INHIBITORS, INCLUDING MULTI-VALENT PHOSPHOLIPASE INHIBITORS, AND USE THEREOF, INCLUDING AS LUMEN-LOCALIZED PHOSPHOLIPASE INHIBITORS | ILYPSA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056281-A2 | MULTIVALENT INDOLE COMPOUNDS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | ILYPSA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056280-A1 | INDOLE COMPOUNDS HAVING C4-ACIDIC SUBSTITUENTS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | ILYPSA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2006120444-A1 | RESPONSIVE LUMINESCENT LANTHANIDE COMPLEXES | UNIVERSITY OF DURHAM (GB) | 2006-11-16 | — | — | WO | disclosed |
| EP-0480745-A2 | Substituted dihydrothieno-thiophene-2-sulfonamides and dioxides thereof | MERCK & CO. INC. (US) | 1992-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318492-A1 | INDOLE COMPOUNDS HAVING C4-ACIDIC SUBSTITUENTS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | PLA2G4A, PLA2G1B, PLA2G4B | TSHR 2153/4885CYP2D6 1552/4885CYP2C19 1737/4885 |
| US-20070135385-A1 | Methyl indoxam; obesity; dietectics; antidiabetic agents; insulin resistance; non-insulin dependent diabetes; glucose intolerance; hypercholesterolemia; hypertriglyceridemia; anticholesterol agents; metabolic disorders; foods;bioavailability; side effect reduction | GPR119, INMT, PNLIP | TSHR 2179/4885CYP2D6 245/4885CYP2C19 293/4885 |
| US-20080312431-A1 | Responsive Luminescent Lanthanide Complexes | TPR, NLRP1, NISCH | TSHR 552/4885CYP2D6 2111/4885CYP2C19 2081/4885 |
| US-20070135383-A1 | Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors | PNLIP, PLA2G2E, PLA2G3 | TSHR 3511/4885CYP2D6 2428/4885CYP2C19 1362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.